The present invention concerns
antibody-conjugate having general structure (2):AB-[(L6)-{Z-(L1)n-(L2)o-(L3)p-(L4)q-D}xx]yy (2)wherein AB is an
antibody capable of targeting Trop-2-expressing tumours and D is selected from the group consisting of taxanes, anthracyclines, camptothecins,
epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes such as calicheamicins, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins,
pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, radioisotopes, therapeutic proteins and peptides (or fragments thereof),
kinase inhibitors, MEK inhibitors, KSP inhibitors, and analogues or prodrugs thereof. These
antibody-conjugates exhibit an improved
therapeutic index. The invention further concerns a process for preparing the antibody-conjugate according to the invention, a method for targeting Trop-2-expressing cells, medical uses of the antibody-conjugates according to the invention.